Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Recombinant human erythropoietin (rhEPO) is receiving increasing attention as a potential therapy for prevention of injury and restoration of function in nonhematopoietic tissues. However, the minimum effective dose required to mimic and augment these normal paracrine functions of erythropoietin (EPO) in some organs (e.g., the brain) is higher than for treatment of anemia. Notably, a dose-dependent risk of adverse effects has been associated with rhEPO administration, especially in high-risk groups, including polycythemia–hyperviscosity syndrome, hypertension, and vascular thrombosis. Of note, several clinical trials employing relatively high dosages of rhEPO in oncology patients were recently halted after an increase in mortality and morbidity, primarily because of thrombotic events. We recently identified a heteromeric EPO receptor complex that mediates tissue protection and is distinct from the homodimeric receptor responsible for the support of erythropoiesis. Moreover, we developed receptor-selective ligands that provide tools to assess which receptor isoform mediates which biological consequence of rhEPO therapy. Here, we demonstrate that rhEPO administration in the rat increases systemic blood pressure, reduces regional renal blood flow, and increases platelet counts and procoagulant activities. In contrast, carbamylated rhEPO, a heteromeric receptor-specific ligand that is fully tissue protective, increases renal blood flow, promotes sodium excretion, reduces injury-induced elevation in procoagulant activity, and does not effect platelet production. These preclinical findings suggest that nonerythropoietic tissue-protective ligands, which appear to elicit fewer adverse effects, may be especially useful in clinical settings for tissue protection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2153]
Citations
Cites
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 2,005
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationDerivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citationErythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Latini, R., Xie, Q.-W., Smart, J., Su-Rick, C.-J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406491101 · Cited by 656
Self-citationRisk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Research works printed but not linked: 6
- D. Santini, B. Vincenzi, A. La Cesa, V. Virzi, F. Navajas, V. Malafarina, G. Dicuonzo, R. Cassandro, V. Esposito, V. Montesarchio, et al. Anticancer Res 25, 669–674 (2005).
- N. D. Vaziri, X. J. Zhou, J. Smith, F. Oveisi, K. Baldwin, R. E. Purdy Am. J. Physiol 269, F838–F845 (1995).
- M. Nowicki J. Hum. Hypertens 9, 81–88 (1995).
- A. Lin, J. Ryu, D. Harvey, B. Sieracki, S. Scudder, T. Wun Gynecol. Oncol, 2006).
- 10.1016/s0008-6363(96)00066-1 · doi:10.1016/s0008-6363(96)00066-1 · Paper page
- 10.1093/oxfordjournals.ndt.a027361 · doi:10.1093/oxfordjournals.ndt.a027361 · Paper page
Cited by
Items 101–136 of 136
Vasculoprotective Effects of Erythropoietin: New Developments and New Alternatives
Kiernan, T. J., & Simari, R. D. (2006) · Circulation Research · doi:10.1161/01.res.0000228463.96905.45 · Cited by 3
Renoprotective effects of erythropoietin
Katavetin, P., Eiam‐Ong, S., & Nangaku, M. (2007) · Asian Biomedicine · doi:10.5372/abm.v1i2.111 · Cited by 2
Ivanov, I., Никифоров, А. С., Венгерович, Н. Г., Perelygin, V. V., & Proshina, Y. A. (2020) · Pharmacy Formulas · doi:10.17816/phf21382 · Cited by 2
Studies on aquaporin 4, a molecular determinant of brain water homeostasis
Gunnarson, E. (2006) · Figshare · Cited by 2
Erythropoietic neuroprotection: Holy Grail or potential to fail?
Pavenski, K., Hare, G. M. T., & Mazer, C. D. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2305-2 · Cited by 2
Matějková, Š. (2013) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-3466 · Cited by 2
Liu, H., Ren, J., Hu, Y., Yang, Y., Sun, H., Fang, H., Yan, G., Han, Y., & Wang, X. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01365-5 · Cited by 2
Self-citationActualités dans la prise en charge de l’anémie Congrès mondial de Néphrologie 2009
Verhelst, D. (2010) · Néphrologie & Thérapeutique · doi:10.1016/s1769-7255(10)70008-0 · Cited by 2
Maghsoudi, A., Zaringhalam, J., Moosavi, M., & Eidi, A. (2021) · Physiology and Pharmacology · doi:10.52547/phypha.26.3.3 · Cited by 1
Extrahematopoietic Actions of Erythropoietin
Brines, M. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00024-6 · Cited by 1
Self-citationNew therapeutic hypothesis for infantile extrinsic hydrocephalus
Kameda, M., Kajimoto, Y., & Wanibuchi, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1215560 · Cited by 1
(2006) · Kidney International · doi:10.1038/sj.ki.5001688 · Cited by 1
The protective effects of erythropoietin on photoreceptor damage by formaldehyde
Khoshnood, M. M., Zareie, M., Amiri, A., Zarenezhad, A., Zarenezhad, E., & Esfandiari, A. (2016) · Nepalese Journal of Ophthalmology · doi:10.3126/nepjoph.v8i1.16151 · Cited by 1
Effekt von Darbepoetin alfa auf die geschädigte Niere am ApoE(-/-) Mausmodell
Karpe, B. (2008) · Cited by 1
Leuvenink, H. G. D., & Ploeg, R. J. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3343-1.50013-x · Cited by 1
Self-citationKim, C., & Lee, C.-H. (2011) · 대한구강악안면외과학회지 · doi:10.5125/jkaoms.2011.37.1.9 · Cited by 1
Stankuvienė, A. (2010) · Lithuanian University of Health Sciences · Cited by 1
Tissue Protection and Regeneration Aided by Erythropoietin and Erythropoietin-derived Peptides
Fliser, D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380928-5.10005-3
Anemia and Progression of Chronic Kidney Disease
Fliser, D., & Bahlmann, F. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-857-7_31
Hirashio, S., Masaki, T., Kagimura, T., & Narita, I. (2025) · Nephrology · doi:10.1111/nep.70140
Targeting the reperfusion injury salvage kinase pathway in the clinical setting
Ludman, A. J. (2011) · UCL Discovery (University College London)
Possible Protective Role of Erythropoietin in Diabetic Cardiomyopathy in Rats
Rabei, M. R., Abd-Elmoniem, H. A., Sarhan, M., Abo-Elmaaty, N., & Ali, L. S. (2017) · Bulletin of Egyptian Society for Physiological Sciences · doi:10.21608/besps.2017.8231
Sepsis et dysfonction cardiovasculaire : nouvelles pistes thérapeutiques
Blet, A. (2016) · theses.fr (ABES) · doi:10.70675/f618d96fz3ae4z41eaz9bf5za614ee911c33
Erythropoietin in post-resuscitation neurological recovery: is there light at the end of the tunnel?
Kupnik, D., & Grmec, Š. (2007) · Signa Vitae · doi:10.22514/sv21.042007.2
Patel, T. V., & Singh, A. K. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3694-2_2
Hooshmandi, E., Moosavi, M., Katinger, H. W. D., Sardab, S., Ghasemi, R., & Maghsoudi, N. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05516-1
Maltaneri, R. E. (2018) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Microencapsulación de células con fines terapeúticos: avances en la biocompatibilidad
Murua Ugarte, A. (2010) · Communities in ADDI (University of the Basque Country)
Performance-enhancing strategies for deceased donor kidneys
van Rijt, G. (2014) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Functional Repair of Brain Death-Induced Injury
Leuvenink, H. G. D., Seelen, M. A., & Ploeg, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4304-9_24
Self-citationShould we look after the brain to protect kidney function in deceased donor renal transplant?*
Graziani, G., Moroni, L., & Ponticelli, C. E. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d3ab67
Kræmer, T. (2012) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-2818
Erythropoietin in vasospasm. From bench to bedside?
Welling, L. C., Welling, M. S. S., Figueiredo, E. G., & Teixeira, M. J. (2014) · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · doi:10.1055/s-0038-1626221
Henke, M., Weißenberger, C., & Pajonk, F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4356
Metadata
- Authors
- Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., Ghezzi, P., Zanetti, A., Kaushansky, K., Fox, N. E., Cerami, A., & Brines, M.
- Affiliations
- Verona Pharma (United Kingdom) (GB)
- University of Utah (US)
- Departments of Medicine and Physiology, University of Utah and Veterans Affairs Medical Centers, Salt Lake City, UT 84148;
- University of Groningen (NL)
- Mayo Clinic (US)
- University of Groningen, 9700 AB, Groningen, The Netherlands;
- Mario Negri Institute for Pharmacological Research (IT)
- University of California San Diego (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-04-11
- Volume
- 103
- Issue
- 15
- Pages
- 5965-5970
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106292297
- Cited by
- 127
- References
- 62
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 5 · 2013: 9 · 2012: 7
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Cancer Institute (R01CA031615)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- recombinant human erythropoietin, carbamylated erythropoietin, erythropoietin receptor, heteromeric receptors, procoagulant activity, platelet count, blood pressure, renal blood flow, sodium excretion, tissue protection, thrombosis, dose-dependent adverse effects, paracrine effects
- MeSH terms
- Animals, Blood Coagulation, Blood Pressure, Bone Marrow Cells, Cell Line, Coagulants, Endothelium, Vascular, Erythropoietin, Hematopoiesis, Hemodynamics, Humans, Renal Circulation, Stem Cells, Umbilical Veins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.